Company Description
MyMD Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company.
It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms.
Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.
The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy.
The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs.
The company was founded in 2014 and is headquartered in Baltimore, Maryland.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Ian Rhodes CPA |
Contact Details
Address: 855 N. Wolfe Street, Suite 601 Baltimore, Maryland 21205 United States | |
| Phone | 856-848-8698 |
| Website | mymd.com |
Stock Details
| Ticker Symbol | MYMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001321834 |
| CUSIP Number | 00973E409 |
| ISIN Number | US62856X2018 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher C. Chapman Jr., M.D. | President, Chief Medical Officer and Director |
| Ian Rhodes CPA | Interim Chief Financial Officer |
| Dr. Adam Kaplin M.D., Ph.D. | Chief Scientific Officer |
| Dr. Jenna Brager M.S., Ph.D., R.N. | Executive Vice President of Drug Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 24, 2024 | 8-K | Current Report |
| Jun 21, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 20, 2024 | 8-K/A | [Amend] Current report |
| Jun 20, 2024 | PRE 14A | Other preliminary proxy statements |
| Jun 17, 2024 | 8-K | Current Report |
| May 31, 2024 | D | Notice of Exempt Offering of Securities |
| May 31, 2024 | D | Notice of Exempt Offering of Securities |
| May 30, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| May 23, 2024 | 8-K | Current Report |